



PRESS RELEASE

FOR IMMEDIATE RELEASE

Invictus appoints Dr David Kingston as Chair of Scientific Advisory Board

Melbourne Victoria (19 March 2018) – Invictus Biotechnology Pty. Ltd., a private Australian biotechnology company developing and commercialising evidence-based nutraceuticals and pharmaceuticals based on a natural product (tocotrienols), today announced that it has appointed Dr David Kingston as Chair of its Scientific Advisory Board.

Dr Kingston was formerly the Medical Director of Roche Australia where he was involved in all product lifecycle phases from phase 1 to 4 including clinical development, regulatory, PBS listing and medical affairs for more than 40 new products.

Invictus Biotechnology's Executive Chairman, Dr Glenn Tong, said:

"David has been an integral part of the team that developed Invictus Biotechnology's assets to date and we are looking forward to continuing to benefit from his extensive experience in product development as we launch our two dietary supplement products in the US and progress our clinical development program with two novel delivery platforms."

"I have previously worked closely with Dr Tong and Professor Mathai to advance Invictus Biotechnology's MELT3 delivery platform and both its nutraceutical and prescription medicine development programs and I am very excited to continue my contributions to add value to these assets!" added Dr Kingston.



Invictus Biotechnology is in the process of working with Dr Kingston to recruit the rest of the Scientific Advisory Board.

Investor and Media Enquiries:

Dr Douglas Pretsell, Investor and Media Relations
Ph: +61 (0) 409 908 553

Corporate enquiries:

Dr Glenn Tong, Executive Chairman
Ph: +61 (0) 412 193 350

About Invictus Biotechnology

Invictus Biotechnology Pty. Ltd. is a private Australian biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, hyperlipidaemia, hypertension and diabetes. Invictus Biotechnology owns and controls patent and other intellectual property rights for novel approaches to delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

About Dr David Kingston MBBS, BPharm, Bsc

Dr Kingston has many years' experience in the pharmaceutical industry and worked in many therapeutic areas including oncology, virology, diabetes, cardiovascular, CNS and transplant amongst others. As Medical Director of Roche Australia he has been involved in all product lifecycle phases from phase 1 to 4 including clinical development, regulatory, PBS listing and medical affairs for more than 40 new products. Also as Head of Clinical Development for the Asia pacific region he has been involved in establishing units in many Asian countries, planning studies in the region and representing the region on the global leadership team. David is now a consultant medical adviser to several companies and involved in clinical studies of many new medicines.